Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7821657 in Locally Advanced and/or Metastatic Solid Tumors
NCT07883577Phase 1Not yet recruiting
- Sponsor
- Roche
- Start
- Oct 2026
- Primary completion
- May 2030
01
Overview
Phase 1, open-label trial of RO7821657 in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Roche. Primary endpoints: Incidence and Severity of Adverse Events at 27 months, Nature and Frequency of Dose-limiting Toxicities and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
RO7821657
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07883577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883577.